Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Total Current Liabilities (2023 - 2025)

Kura Oncology (KURA) has disclosed Total Current Liabilities for 3 consecutive years, with $117.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 48.61% to $117.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $117.0 million, a 48.61% increase, with the full-year FY2025 number at $117.0 million, up 48.61% from a year prior.
  • Total Current Liabilities was $117.0 million for Q4 2025 at Kura Oncology, down from $121.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $121.3 million in Q3 2025 to a low of $19.2 million in Q1 2023.
  • A 3-year average of $60.5 million and a median of $37.8 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 39.97% in 2024, then skyrocketed 220.39% in 2025.
  • Kura Oncology's Total Current Liabilities stood at $35.3 million in 2023, then surged by 123.21% to $78.7 million in 2024, then surged by 48.61% to $117.0 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Total Current Liabilities are $117.0 million (Q4 2025), $121.3 million (Q3 2025), and $107.2 million (Q2 2025).